Literature DB >> 19712273

Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients.

Won Young Tak1, Soo Young Park, Min Kyu Jung, Seong Woo Jeon, Chang Min Cho, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi.   

Abstract

As a pyrimidine analog with potent and sustained antiviral activity against hepatitis B virus, clevudine has been known to have no effect on mitochondrial structure, DNA content, or function. There is little information on the side effects of clevudine, which has not been approved for the treatment of chronic hepatitis B outside of South Korea. We report here two cases of chronic hepatitis B patients who experienced mitochondrial myopathy after clevudine medication. These cases raise concerns about the safety profile of clevudine for the treatment of chronic hepatitis B.

Entities:  

Year:  2009        PMID： 19712273     DOI： 10.1111/j.1872-034X.2009.00515.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


  10 in total

1.  Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.

Authors:  Li Chen; Cai Cheng; Bicui Chen; Yue Zhao; Jiming Zhang; Bin Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-11-14       Impact factor: 2.953

2.  18F-FDG PET/CT of drug-induced myopathy in a patient with chronic hepatitis B on long-term clevudine therapy.

Authors:  Jeong Ah Lee; Hwan Sik Hwang; Dae-Hyun Yoo; Seung Sam Paik; Sung-June Jang; Young Hwan Kim; Min-Ho Lee; Yun Young Choi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

3.  Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.

Authors:  Suk Bae Kim; Il Han Song; Young Min Kim; Ran Noh; Ha Yan Kang; Hyang Ie Lee; Hyeon Yoong Yang; An Na Kim; Hee Bok Chae; Sae Hwan Lee; Hong Soo Kim; Tae Hee Lee; Young Woo Kang; Eaum Seok Lee; Seok Hyun Kim; Byung Seok Lee; Heon Young Lee
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

4.  A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.

Authors:  Su Rin Shin; Byung Chul Yoo; Moon Seok Choi; Dong Ho Lee; Soon Mi Song; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Hepatol Int       Date:  2011-01-01       Impact factor: 6.047

Review 5.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 6.  A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.

Authors:  Karen S Anderson
Journal:  Methods       Date:  2010-05-31       Impact factor: 3.608

Review 7.  A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial disease.

Authors:  Christopher M Bailey; Karen S Anderson
Journal:  Biochim Biophys Acta       Date:  2010-01-18

Review 8.  Emerging antivirals for the treatment of hepatitis B.

Authors:  Xue-Yan Wang; Hong-Song Chen
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells.

Authors:  Yoon-Ok Jang; Xianglan Quan; Ranjan Das; Shanhua Xu; Choon-Hee Chung; Chan Mug Ahn; Soon-Koo Baik; In Deok Kong; Kyu-Sang Park; Moon Young Kim
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067

10.  A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.

Authors:  Won Young Tak; Jin Mo Yang; Byung Ik Kim; Soon Koo Baik; Gab Jin Cheon; Kwan Soo Byun; Do Young Kim; Byung Chul Yoo
Journal:  Hepatol Int       Date:  2014-05-25       Impact factor: 6.047
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.